Eisbach Bio is working on a new class of cancer drugs. These drugs use specific molecules to interfere with the internal mechanisms of cancer cells and block their function. This makes it possible to combat tumors that are resistant to conventional treatments because their Genome constantly changingThis commitment is worth 4.2 million euros (4.5 million dollars) to the Cancer Focus Fund.
“Eisbach’s distinctive and scientifically sophisticated approach to treating common, difficult-to-treat cancers fits perfectly with our goals at the Cancer Focus Fund,”
says Ross Barrett, Founder and Managing Partner of the Cancer Focus Fund.
Eisbach Bio starts clinical study
The US investment fund was established in collaboration with the University of Texas MD Anderson Cancer Center (MD Anderson) to advance promising cancer therapies. The investment will finance a Phase 1/2 clinical trial of Eisbach Bio's lead candidate, EIS-12656. Startup plans to conduct the study for the treatment of refractory advanced solid tumors at MD Anderson.
Regarding the investment Barrett:
"We want to support innovative young companies like Eisbach in rapidly advancing exceptionally promising new cancer drugs into clinical trials with the help of MD Anderson's experienced researchers and clinicians. EIS-12656 has demonstrated the potential to treat many recurrent and refractory tumors more effectively and with fewer side effects than current therapies, and we look forward to following the progress of this exciting first-in-class compound in clinical development. We are also pleased to expand our geographic reach with this first investment in a German-based biotech company with its rich history of biomedical innovation."
Dr. Andreas Ladurner, founder and CSO of Eisbach and Professor and Chair of Physiological Chemistry at the Ludwig Maximilian University of Munich, comments:
"Most cancers contain mechanisms for genome reorganization that play a crucial and very specific role in tumor biology. If we discover how each of these vital mechanisms is selectively regulated, we can exploit unique molecular vulnerabilities. This approach holds great promise for the discovery of new cancer drugs that are both selective and safe."
